Applying leading-edge science at the intersections of disciplines to discover new treatments for movement disorders

About Us

Who We Are

Nine Square Therapeutics is a team of talented and motivated scientists discovering novel small-molecule therapeutics for Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and other neurodegenerative movement disorders – diseases for which patients are urgently awaiting more effective treatments.

Founded by life sciences venture capital firm ATP and leading scientists at the University of California San Francisco (UCSF), Nine Square has the capabilities and depth in computational science to drive drug discovery at an accelerated pace and provide multiple approaches to high value targets, to bring hope and help to people living with debilitating conditions.

What We Do

Roughly 75% of disease-related targets are considered “undruggable”. Nine Square’s mission is to develop small molecule candidates for targets that could not be approached previously. We combine state-of-the-art computational chemistry with a machine-learning-enabled cell profiling platform.

Computational Chemistry

Nine Square was founded to push the frontiers of interdisciplinary science in a search for new cures.

  • Nine Square is combining the latest advances in computational methods with deep expertise in medicinal chemistry, allowing us to focus confidently on difficult targets with compelling biology.
  • Using cutting-edge tools such as molecular dynamics simulations, we develop rigorous models of protein motion and protein-protein interactions that enable us to generate hypothesis-driven, nontraditional chemistry strategies.
  • Our expertise in computational chemistry facilitates a unique approach to high value biological targets with unexploited modalities such as allostery, protein complex stabilization, and pharmacologic activation.

Cell Profiling Platform

Our machine-learning-enabled cell profiling platform allows for:

  • Highly scalable, multi-parameter microscopy and automated image analysis to accelerate drug discovery and validation;
  • Establishment of an imaging-based “finger-print” in cellular disease models to improve translation to in vivo models and patients;
  • Identification of novel disease biomarkers and patient stratification to increase the likelihood of success in clinical trials.

Our People


Board of Directors

Scientific Advisory Board


Join Us

Nine Square Therapeutics is seeking scientists to join our San Francisco Bay Area-based team.